Current Perspectives of Pharmacotherapy in Dentistry and Inflammatory and Ulcerative Oral Mucosal Disorders: A Case Based on Approach to Diagnosis and Therapeutic Management


Friday, November 5, 2021    Live Interactive Webinar 8:00 am - 2:30 pm






The differential diagnosis for infectious and non-infectious inflammatory and ulcerative oral mucosal disorders is extensive. Differential diagnosis of common oral mucosal disorders based on morphology, inciting events and the natural history will be discussed. The overall objective of this course is to provide the participant practical approach to evaluate patients who present with painful oral mucositis and ulcerations.



Upon completion of the course, you will be able to identify:

  • Selection of antibiotics for orofacial infections and the use of antibiotic prophylaxis
  • Selection of drugs for pain, including pre-operative (“pre-emptive”) uses and scientific assessment of efficacy of various agents
  • Comparative clinical features of current injectable local anesthetics, selection and use of new compound topical anesthetics and local anesthetic reversal agents
  • Selection of appropriate drugs for sedation, emergency management and caries prevention.
  • A current approach to formulate differential diagnoses for acute and chronic oral inflammatory and ulcerative lesions
  • The clinical manifestations of ulcerative stomatitis of infectious, autoimmune and neoplastic etiology and the roles of clinical presentation, duration, distribution, location and color in the diagnosis of oral ulcerations
  • Diagnostic guidelines and procedures for autoimmune ulcerative and vesiculobullous and ulcerative oral mucosal diseases
  • Rationale for the therapeutic and preventive management strategies of common oral mucositis and ulcerations.



Tuition | Course Fee


Live Interactive Webinar presentation

CDE Only | 6-hours continuing dental education
$95 - Delta Dental Members, Dentist or Allied Dental Personnel


Course fee is due at time of registration.


Sign Up Today!

About Our Speaker


Arthur H. Jeske, DMD, PhD, is the Associate Dean for Strategic Planning and Continuing Dental Dducation and a professor in the Department of General Practice and Dental Public Health at The University of Texas School of Dentistry at Houston. He earned his PhD in pharmacology and DMD from the Medical College of Georgia. He is a member of the American Dental Association (ADA), Texas Dental Association, and Greater Houston Dental Society and is a fellow of the International College of Dentistry and the American College of Dentistry. Dr. Jeske chaired the ADA's Council on Scientific Affairs in 2004 and has authored numerous articles on the use of drugs in dentistry. He is currently editor-in-chief of Mosby's Dental Drug Reference and an editor of Contemporary Dental Pharmacology.




Nadarajah Vigneswaran, BDS, DMD, DrMedDent, is a professor in the UTHealth School Dentistry in the Department of Diagnostic and Biomedical Sciences. He earned a Dr.Med.Dent in Immunopathology at University of Erlangen, Germany and a DMD at UAB School of Dentistry. He completed his residency in Oral and Maxillofacial Pathology at the Emory University School of Medicine and his Dental Oncology Fellowship at the UAB School of Dentistry. He is an oral and maxillofacial pathologist who is involved in the diagnosis and management of patients with various oral mucosal disorders. He directs the UTSD-Houston Oral and Maxillofacial Pathology Biopsy service, which process approximately 5,000 cases per year, and is one of the largest biopsy services for the dental profession, in this country. He is actively involved in both clinical and laboratory-based research, related to oral cancer and its precursors. His clinical research focuses on evaluating non-invasive diagnostic devices for early diagnosis of oral cancer and its precursor lesions. His basic research involves the development of experimental animal models for pre-clinical testing of molecular targeted diagnostic imaging and therapy. He also has more than 120 peer reviewed scientific publications in high-impact journals and 6 chapters in medical dental textbooks. He has been an invited presenter for national and international research conference and received over $ 7.5 million in grant funding from Federal (NIH), State (CPRIT) and Local (UTHealth CTSA Consortium) as a principal- and co-investigator.


For their continued support and participation in our co-sponsored programs UTHealth School of Dentistry gratefully acknowledges:

Credit Hours


016 Pharmacotherapeutics - Lecture: Hours - 3
739 Diagnosis of Oral Pathology - Lecture: Hours - 3



This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Recognition Program (ADA CERP).


As a courtesy, please register in advance to receive presentation links, course handouts and other timely information. For your convenience, registration will close 30 minutes prior to the start of the presentation.

Live Interactive Webinars are considered as in-classroom setting CE hours by the Texas State Board of Dental Examiners.

Continuing education credits awarded for participation in this Live Interactive Webinar may not apply as in person/ / in-classroom CE hours towards license renewal in all states. It is the responsibility of each participant to verify the requirements of his/her state licensing board(s).



Online Link Opens:
7:30 AM

8:00 AM to 2:30 PM

CDE Course Location:
Virtual CDE | Live Interactive Webinar

Share This

Contact Us
UTHealth School of Dentistry
PACE Center, Continuing Dental Education
7500 Cambridge St., Suite 6152
Houston, TX 77054
Ph: 713-486-4028
Fax: 713-486-4037